FanÃ©lie Jouenne

List of Publications by Year
in descending order

18 papers	213 citations	1478505 6 h-index	1058476 14 g-index
19 all docs	19 docs citations	19 times ranked	369 citing authors

#	Article	IF	Citations
1	CD147 Is a Promising Target of Tumor Progression and a Prognostic Biomarker. Cancers, 2019, 11, 1803.	3.7	85
2	Genetic landscape of adult Langerhans cell histiocytosis with lung involvement. European Respiratory Journal, 2020, 55, 1901190.	6.7	38
3	Macrophage-derived CXCL9 and CXCL11, T-cell skin homing, and disease control in mogamulizumab-treated CTCL patients. Blood, 2022, 139, 1820-1832.	1.4	30
4	Baseline Genomic Features in BRAFV600-Mutated Metastatic Melanoma Patients Treated with BRAF Inhibitor + MEK Inhibitor in Routine Care. Cancers, 2019, 11, 1203.	3.7	10
5	Development and validation of a liquid chromatography tandem mass spectrometry quantification method for 14 cytotoxic drugs in environmental samples. Rapid Communications in Mass Spectrometry, 2020, 34, e8594.	1.5	9
6	Phase Iâ€“II Open-Label Multicenter Study of Palbociclib + Vemurafenib in BRAFV600MUT Metastatic Melanoma Patients: Uncovering CHEK2 as a Major Response Mechanism. Clinical Cancer Research, 2021, 27, 3876-3883.	7.0	8
7	Conservative management is effective in unicystic ameloblastoma occurring from the neonatal period: A case report and a literature review. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2020, 129, e234-e242.	0.4	6
8	Clinicopathologic and molecular characterization of melanomas mutated for CTNNB1 and MAPK. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2022, 480, 475-480.	2.8	6
9	Dabrafenib and trametinib exposure-efficacy and tolerance in metastatic melanoma patients: a pharmacokineticâ€“pharmacodynamic real-life study. Cancer Chemotherapy and Pharmacology, 2021, 88, 427-437.	2.3	5
10	Clinical significance of BRAF/NRAS concurrent mutations in a clinicâ€based metastatic melanoma cohort. British Journal of Dermatology, 2020, 182, 1281-1283.	1.5	3
11	Phase I-II open label multicenter study of PD0332991 in BRAF^{V600mut} metastatic melanoma patients harboring CDKN2A loss and RB1 expression and treated with vemurafenib.. Journal of Clinical Oncology, 2019, 37, 9545-9545.	1.6	3
12	Challenges in the diagnosis of primary cutaneous CD 30 + anaplastic largeâ€cell lymphoma. British Journal of Dermatology, 2019, 182, 233-234.	1.5	2
13	A Melanoma-Tailored Next-Generation Sequencing Panel Coupled with a Comprehensive Analysis to Improve Routine Melanoma Genotyping. Targeted Oncology, 2020, 15, 759-771.	3.6	2
14	The PI3K/mTOR Pathway Is Targeted by Rare Germline Variants in Patients with Both Melanoma and Renal Cell Carcinoma. Cancers, 2021, 13, 2243.	3.7	2
15	High-grade trichoblastic carcinoma with sarcomatoid differentiation harboring TP53 and PIK3CA mutations. Annales De Dermatologie Et De Venereologie, 2022, 149, 74-77.	1.0	2
16	The MAPK Pathway in Pulmonary Langerhans Cell Histiocytosis. Archivos De Bronconeumologia, 2022, , .	0.8	2
17	Custom pyrosequencing assay to detect short BRAF deletions in Langerhans cell histiocytic lesions. Journal of Clinical Pathology, 2021, 74, 533-536.	2.0	0
18	The key role of oncopharmacology in therapeutic management, from common to rare cancers: A literature review. Therapie, 2020, 75, 183-193.	1.0	0